Company Directory - Research & Development
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics.
We are the leading population genomics company operating at the intersection of clinical care, research, and genomics. Our end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care.
Helsinn has become one of the world’s leading cancer care and rare diseases companies, with a comprehensive portfolio of products and therapies helping to improve the lives of patients all around the world. We work with a host of longstanding worldwide partners who share our vision and values, with a unique business model combining integrated early- and late-stage licensing programs to complement our own drug discovery and development.
Helvetica Health Care is a global health care organisation based in Geneva, Switzerland, in the renowned Swiss BioValley. Our commitment to quality is evident in our product offerings, which include monoclonal antibodies, polyclonal antibodies.
At HiberCell, we are focused on developing novel therapeutics to overcome foundational barriers that prevent patients from living longer, cancer-free lives.
Founded in 2015, InVitro Cell Research, LLC (ICR) is a privately funded company focused on regenerative and preventive personalized medicine. We are dedicated to discovering and developing interventions to slow and reverse biological aging and prevent major age-related diseases.
IDEAYA is a synthetic lethality-focused precision medicine oncology company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go.
We combine the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry.
